• Tetrahydromagnolol: Empowering Translational CB2 Research

  2026-05-26

  This article offers translational researchers an advanced, mechanistic perspective on how tetrahydromagnolol, a highly selective peripheral CB2 receptor agonist, can transform cannabinoid receptor research and anti-inflammatory assay design. By bridging recent insights in GPCR signaling and metastatic mechanisms, it provides strategic guidance on deploying tetrahydromagnolol in experimental workflows, highlights its differentiation from conventional reagents, and evaluates its implications for next-generation anti-metastatic strategies.

• Antiadipogenic Compounds from Bauhinia divaricata: Triacetin

  2026-05-25

  The reference study systematically analyzed Bauhinia divaricata extracts for their antiadipogenic and lipolytic effects using in vitro models. It identified triacetin among major bioactive compounds, highlighting its potential relevance for metabolic research and obesity intervention strategies.

• Ziprasidone Augmentation of Escitalopram in Anxious Depressi

  2026-05-25

  This article evaluates a recent clinical study investigating the efficacy of ziprasidone augmentation in patients with major depressive disorder, focusing on those with anxious depression already receiving escitalopram. The findings clarify the nuanced impact of adjunctive antipsychotic therapy on depression and anxiety outcomes, offering insights for translational antidepressant research.

• FLOT1–FOSL2–EphA2 Axis Modulates Microglial Polarization in

  2026-05-24

  The referenced study uncovers how the FLOT1–FOSL2 interaction drives EphA2 transcription, activating the p38/MAPK pathway and promoting pro-inflammatory microglial polarization in Alzheimer's disease models. These findings identify a mechanistic axis regulating neuroinflammation and suggest novel therapeutic targets for modulating microglial activity and cognitive outcomes in AD.

• Graphene Nanomaterials Trigger Apoptosis in Melanoma Cells

  2026-05-23

  A recent study from Xiamen University demonstrates that graphene film induces apoptosis and hypoxic stress in melanoma cells via caspase-dependent pathways. These findings clarify the mechanistic underpinnings of graphene's anticancer effects and offer new avenues for apoptosis-targeted cancer research.

• Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one): T

  2026-05-22

  Explore the multi-mechanistic action of Apigenin, a plant-derived HDAC inhibitor, in advanced cancer and neurodegeneration research. This article uniquely analyzes network pharmacology insights and practical workflow implications for malignant mesothelioma and Alzheimer's disease models.

• DFCP1 Regulates Starvation-Driven ATGL Lipolysis in Lipid Dr

  2026-05-22

  This study identifies DFCP1 as a nutrient-sensitive regulator of lipid droplet catabolism, directly modulating ATGL-mediated lipolysis during starvation. The research advances understanding of lipid mobilization mechanisms and highlights methodological considerations for protein integrity in related assays.

• Clarithromycin as a CYP3A Inhibitor: Advanced Insights for D

  2026-05-21

  Explore how Clarithromycin, a benchmark CYP3A inhibitor, enables advanced drug-drug interaction research and pharmacokinetic studies. This article uncovers underexplored mechanisms, technical protocols, and practical distinctions for rigorous assay design.

• CGP 55845 Hydrochloride: Advanced GABAB Receptor Antagonist

  2026-05-21

  Unlock precise GABAB receptor modulation with CGP 55845 hydrochloride. This guide translates breakthrough astrocyte-neuron research into optimized, reproducible in vitro workflows—empowering synaptic transmission and neurotransmitter release studies with actionable parameters.

• Viral-Induced RIPK3 Degradation Modulates Necroptosis and In

  2026-05-20

  Liu et al. revealed that a class of orthopoxvirus proteins actively induce proteasomal degradation of the necroptosis adaptor RIPK3, thereby suppressing necroptotic cell death and modulating virus-induced inflammation. This mechanism highlights a pivotal viral strategy for immune evasion and underscores the significance of host-pathogen coevolution in shaping inflammatory responses.

• Nirmatrelvir (PF-07321332): Enhancing SARS-CoV-2 Research Wo

  2026-05-20

  Nirmatrelvir (PF-07321332) offers researchers a highly selective tool for dissecting SARS-CoV-2 3CL protease function, driving translational advances in COVID-19 antiviral research. This guide distills best practices, experimental enhancements, and troubleshooting strategies for maximizing the impact of this benchmark inhibitor in viral replication studies.

• Strategic Insights: a-MSH, amide in Pigmentation & Inflammat

  2026-05-19

  This thought-leadership article explores the mechanistic and translational value of alpha-melanocyte-stimulating hormone amide (a-MSH, amide) in pigmentation regulation and anti-inflammatory research. Integrating recent findings on melanogenesis pathways, comparative approaches, and next-generation assay optimization, the article is a strategic guide for translational researchers aiming to advance both mechanistic understanding and practical application of APExBIO’s a-MSH, amide.

• Phosphatase Inhibitor Cocktail 2: Optimizing Phosphoprotein

  2026-05-19

  Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) from APExBIO empowers researchers to preserve protein phosphorylation with unmatched reliability across Western blotting, kinase assays, and signaling workflows. Explore how precise protocol parameters, evidence-driven troubleshooting, and insights from recent genomic studies converge to maximize assay fidelity in complex biological samples.

• Valemetostat’s Dual EZH1/2 Inhibition in Adult T-cell Leukem

  2026-05-18

  Valemetostat introduces a dual inhibition strategy targeting EZH1 and EZH2, two key methyltransferases implicated in the oncogenic epigenetic landscape of adult T-cell leukemia/lymphoma (ATL). The study offers the first clinical approval and robust evidence for improved clinical response rates in relapsed or refractory ATL, with implications for epigenetic-targeted therapies in hematologic malignancies.

• Calnexin-Dependent Modulation of CFTR Variant Rescue by Corr

  2026-05-18

  This study systematically maps how the ER chaperone calnexin influences the expression and pharmacological rescue of over 200 clinical CFTR variants, highlighting domain- and mutation-specific effects. These findings provide mechanistic insight crucial for developing precision CFTR modulator therapies and optimizing research protocols.

453 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page